Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma

被引：27

作者：

Bauwens, D

Maerevoet, M

Michaux, L

Théate, I

Hagemeijer, A

Stul, M

Danse, E

Costantini, S

Vannuffel, P

Straetmans, N

Vekemans, MC

Deneys, V

Ferrant, A

Van Den Neste, E

机构：

[1] Clin Univ St Luc, Dept Haematol, B-1200 Brussels, Belgium

[2] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium

[3] Clin Univ St Luc, Dept Biol Clin, B-1200 Brussels, Belgium

[4] Clin St Pierre, Dept Haematol, Ottignies, Belgium

[5] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium

[6] Inst Pathol & Genet, Loverval, Belgium

[7] Hop Jolimont, Dept Haematol, Haine St Paul, Belgium

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 131卷 / 03期

关键词：

rituximab; chlorambucil; mantle cell lymphoma; B-cell non-Hodgkin lymphoma; immuno-chemotherapy;

D O I：

10.1111/j.1365-2141.2005.05777.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.

引用

页码：338 / 340

页数：3

共 9 条

[1]

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[2]

Chow KU, 2002, HAEMATOLOGICA, V87, P33

[3]

Fisher Richard I, 2004, Hematology Am Soc Hematol Educ Program, P221

[4]

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Forstpointner, R ;

Dreyling, M ;

Repp, R ;

Hermann, S ;

Hänel, A ;

Metzner, B ;

Pott, C ;

Hartmann, F ;

Rothmann, F ;

Rohrberg, R ;

Böck, HP ;

Wandt, H ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2004, 104 (10) :3064-3071

[5]

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK) [J].

Ghielmini, M ;

Schmitz, SFH ;

Cogliatti, S ;

Bertoni, F ;

Waltzer, U ;

Fey, MF ;

Betticher, DC ;

Schefer, H ;

Pichert, G ;

Stahel, R ;

Ketterer, N ;

Bargetzi, M ;

Cerny, T .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :705-711

[6]

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival [J].

Howard, OM ;

Gribben, JG ;

Neuberg, DS ;

Grossbard, M ;

Poor, C ;

Janicek, MJ ;

Shipp, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1288-1294

[7]

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma [J].

Martinelli, G ;

Laszlo, D ;

Bertolini, F ;

Pastano, R ;

Mancuso, P ;

Calleri, A ;

Vanazzi, A ;

Santoro, P ;

Cavalli, F ;

Zucca, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (02) :271-277

[8]

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease [J].

Orchard, J ;

Garand, R ;

Davis, Z ;

Babbage, G ;

Sahota, S ;

Matutes, E ;

Catovsky, D ;

Thomas, PW ;

Avet-Loiseau, H ;

Oscier, D .

BLOOD, 2003, 101 (12) :4975-4981

[9]

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group [J].

Vandenberghe, E ;

De Wolf-Peeters, C ;

Hudson, GV ;

Hudson, BV ;

Pittaluga, S ;

Anderson, L ;

Linch, DC .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :842-847

← 1 →